Figure 1

Increased metastasis after short-term treatment with bevacizumab. Forty mice were assigned into four groups (PBS, bevacizumab, cisplatin and bevacizumab + cisplatin). Mean photon counts of each group were quantified. (A) Tumor growth and metastasis were monitored by bioluminescence at 1 and 4 weeks after treatment. A representative experiment is shown. (B) Short-term bevacizumab treatment resulted in accelerated extrapulmonary metastasis at 4 weeks after treatment. Extrapulmonary metastases were found in the livers and legs. The ratio of metastasis of each group was measured. (C) Quantification of bioluminescence showed inhibited tumor growth in bevacizumab and/or cisplatin treatment groups at 1 week after treatment, compared with that of the PBS group. Bevacizumab + cisplatin treatment inhibited tumor growth, compared with that of cisplatin at 1 week after treatment. (D) Quantification of bioluminescence showed no significant difference in tumor growth between bevacizumab and PBS groups 4 weeks after treatment. Bevacizumab + cisplatin treatment inhibited tumor growth compared with that of cisplatin at 4 weeks after treatment. *P < 0.05, **P < 0.01.